Pharmaron’s third-quarter revenue came in slightly above the Bloomberg consensus, with CMC leading in revenue and new-order growth; exchange-rate effects and higher finance costs caused net profit attributable to shareholders to grow more slowly than revenue.
Bloomberg reports that the two companies are in advanced talks. Bernstein believes an acquisition fits Marvell’s optical strategy, but the size of the deal could make all-cash financing difficult and change laser customers’ purchasing choices.
Year-over-year search revenue growth fell from 17% to 12%, while rising AI search usage is temporarily weighing on monetization; cloud revenue grew 103%, but computing costs and capital expenditure are pressuring profits and cash flow. Bernstein lowered its price target to $325.
SK Hynix’s third-quarter profit beat expectations, driven by memory prices; Microsoft and Alphabet posted strong cloud growth, but Alphabet’s search revenue and overall profit fell short of Goldman Sachs estimates. Goldman also expects the Federal Reserve to raise rates once more in December.
Nomura estimates that Hengrui's third-quarter drug sales grew 4.9% year on year, reversing the previous quarter's decline. A sharp increase in collaboration revenue pushed total revenue and net profit attributable to shareholders above Bloomberg consensus estimates, although full-year growth in innovative drug sales may fall short of the company's target set at the start of the year.
Bernstein expects Democrats to be in a position to take control of the House, while the Senate outcome is too close to call. If some provisions of the healthcare legislation are delayed, pressure on Medicaid enrollment and insurer margins could ease. Hospitals would also benefit, but the firm believes much of the upside is already reflected in valuations.
Bernstein estimates that the combined transaction value represents about 3.5% of the entire U.S. grocery market and about 23% of the online grocery market; looking only at third-party platforms, the share rises to 88%. The deal is still under negotiation, and financing arrangements have not been determined.
Bernstein resumed its repair-shop survey after 14 years: O'Reilly's preferred-supplier rate rose in markets where it operates compared with 2012, but repair-shop relationships are long-standing and orders highly concentrated. Parts availability and delivery capabilities remain the foundation of competition.
Branded checkout growth fell to 1% in the third quarter, but expense controls drove better-than-expected earnings. Bernstein sees financial services becoming a new source of transaction profit and is watching whether AI agent shopping can reshape PayPal’s value.
Molina’s third-quarter adjusted earnings per share exceeded Bernstein’s expectations but fell by more than half year over year. Preliminary renewal rates for 2027 have improved and could ease pressure from medical costs; membership losses and delays to new contracts, however, weigh on the revenue outlook.
Corning’s third-quarter revenue and earnings per share both exceeded expectations, with optical communications the main contributor, but free cash flow fell short. The company’s fourth-quarter revenue guidance was below Bernstein’s forecast, while its earnings-per-share guidance was higher.
Coca-Cola raised its 2026 guidance, and Bernstein sees little execution risk remaining this year. But once the volume boost from the World Cup enters the comparison base, price and mix will need to improve to sustain growth in 2027.
Third-quarter revenue and earnings per share both beat expectations. Bernstein believes the scale of the OpenAI project deployment could bring greater growth, but the company's 2027 margin guidance is below the firm's forecast, and capacity expansion is expected to turn free cash flow negative.
Improved vehicle utilization in one-way truckload transportation drove revenue per truck up approximately 34% year over year in the third quarter; however, fuel, driver and insurance costs eroded profits, and Goldman Sachs again cut its fourth-quarter earnings-per-share forecast.
WuXi AppTec’s new orders and early-stage R&D demand are improving; TrendForce expects memory price increases to continue through the first half of 2028. Japanese bank valuations have fallen, while deposit competition at HSBC is weighing on net interest income expectations.
Hard-drive capacity shipments and prices both rose, and Seagate’s guidance for the next quarter was well above market expectations. Potential industry capacity expansion and lower peer valuations, however, also constrain the stock’s valuation.
Revenue and operating margin both exceeded market expectations, but ratings growth fell short of Goldman Sachs’ forecast; the raised full-year revenue guidance remains below the previous market consensus.
Johnson & Johnson management expects operational sales growth to accelerate in 2027 and says the medical devices business had rebounded in October. Longer-term growth depends on new product launches and pipeline progress, particularly expansion into solid tumors.
Mo-rez achieved a confirmed response rate of 62% in platinum-resistant ovarian cancer, while global data for Ris-rez in small-cell lung cancer were also close to those from a Chinese study. Goldman Sachs sees both assets as competitive, but higher doses were associated with more serious adverse events, and the near-term focus remains oncology drug commercialization.
Earlier concentrate shipments helped Coca-Cola beat third-quarter revenue and profit expectations, and the company raised its full-year earnings per share guidance. Goldman Sachs is positive on operating momentum but believes next year's asset sale, currency pressures and higher valuation limit the stock's appeal.
